Evidence map›Paper›PMID 37869794›Full record

ArticleThe Biochemical journal2023

Activating mutations drive human MEK1 kinase using a gear-shifting mechanism.

Keshav Patil, Yiming Wang, Zhangtao Chen, Krishna Suresh, Ravi Radhakrishnan

Open access · hybridAbstract read
In one paragraph

Article in The Biochemical journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Keshav PatilDepartment of Chemical and Biomolecular Engineering, University of Pennsylvania, Philadelphia, PA, U.S.A.
Yiming WangDepartment of Chemical and Biomolecular Engineering, University of Pennsylvania, Philadelphia, PA, U.S.A.
Zhangtao ChenDepartment of Bioengineering, University of Pennsylvania, Philadelphia, PA, U.S.A.
Krishna SureshDepartment of Bioengineering, University of Pennsylvania, Philadelphia, PA, U.S.A.
Ravi RadhakrishnanDepartment of Chemical and Biomolecular Engineering, University of Pennsylvania, Philadelphia, PA, U.S.A.ORCID 0000-0003-0686-2851
University of Pennsylvania · US

Funding

A physical sciences approach to investigate the role of exosomes in metastatic progressionU01CA250044 · NCI · UNIVERSITY OF PENNSYLVANIA · PI GUO, WEI, RADHAKRISHNAN, RAVI · 2021 to 2025
$3.9M
Multiscale Modeling to Optimize Inhibition of Oncogenic ERK Pathway SignalingR01CA244660 · NCI · YALE UNIVERSITY · PI HLAVACEK, WILLIAM S, KHOLODENKO, BORIS N · 2020 to 2024
$3.4M
A plasticity and reprogramming paradigm for therapy resistance at the single cell levelU01CA227550 · NCI · UNIVERSITY OF PENNSYLVANIA · PI RADHAKRISHNAN, RAVI, RAJ, ARJUN · 2018 to 2022
$3.3M
NCI NIH HHS R01 CA244660NCI NIH HHS U01 CA227550NCI NIH HHS U01 CA250044
6 · The paper itself

Abstract

There is an unmet need to classify cancer-promoting kinase mutations in a mechanistically cognizant way. The challenge is to understand how mutations stabilize different kinase configurations to alter function, and how this influences pathogenic potential of the kinase and its responses to therapeutic inhibitors. This goal is made more challenging by the complexity of the mutational landscape of diseases, and is further compounded by the conformational plasticity of each variant where multiple conformations coexist. We focus here on the human MEK1 kinase, a vital component of the RAS/MAPK pathway in which mutations cause cancers and developmental disorders called RASopathies. We sought to explore how these mutations alter the human MEK1 kinase at atomic resolution by utilizing enhanced sampling simulations and free energy calculations. We computationally mapped the different conformational stabilities of individual mutated systems by delineating the free energy landscapes, and showed how this relates directly to experimentally quantified developmental transformation potentials of the mutations. We conclude that mutations leverage variations in the hydrogen bonding network associated with the conformational plasticity to progressively stabilize the active-like conformational state of the kinase while destabilizing the inactive-like state. The mutations alter residue-level internal molecular correlations by differentially prioritizing different conformational states, delineating the various modes of MEK1 activation reminiscent of a gear-shifting mechanism. We define the molecular basis of conversion of this kinase from its inactive to its active state, connecting structure, dynamics, and function by delineating the energy landscape and conformational plasticity, thus augmenting our understanding of MEK1 regulation.

Indexed as

NeoplasmsGain of Function MutationHumansMutationactivating mutationsconformational plasticitydynamical correlationenhanced samplingoncogenic driver

Identifiers

PMID37869794
PMCPMC10872882
OpenAlexW4387866351

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.